Fulgent Genetics

Fulgent Genetics is a technology-driven company based in the U.S. that specializes in comprehensive genetic testing and precision medicine solutions, particularly in oncology and genomic diagnostics. Founded in 2011, it was the first clinical laboratory in the U.S. to offer copy number variation detection using next-generation sequencing technology. The company aims to improve the quality of human life by providing accessible and affordable genetic testing services. Fulgent offers a variety of genetic testing services, including hereditary cancer panels, pharmacogenetic testing, carrier screening, and prenatal cell-free DNA screening. The company also provides sequencing and laboratory diagnostics through its facilities in Alpharetta, Phoenix, and El Monte. Notable products include HelioLiver, Beacon Carrier Screening, and the recently introduced KNOVA prenatal screening test. In addition to diagnostics, Fulgent is involved in drug development for cancer treatment, collaborating with institutions like Moffitt Cancer Center. Fulgent Genetics serves healthcare providers such as pathologists and oncologists, and it has partnerships with government entities, including a contract with the U.S. Department of Veterans Affairs. With a network of world-class laboratories, Fulgent is committed to delivering advanced genetic testing services tailored to client needs.